SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE) -- Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional systems biology, announced today promising data utilizing the company’s proprietary Single Cell Network Profiling (SCNP) technology in rheumatoid arthritis.
The study results were featured in an oral presentation delivered by S. Louis Bridges, Jr., M.D., Ph.D., Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, Director, Division of Clinical Immunology and Rheumatology, University of Alabama School of Medicine, and titled, Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling (Abstract 876), at the 2013 ACR/ARHP Annual Meeting.
Additional program results were featured in a poster presentation, Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients (Abstract 2288).
To generate these results, the researchers applied Nodality’s proprietary SCNP technology, a multiparametric flow cytometry-based assay that reveals functional biology by measuring the activity of protein pathway signaling at the single cell level.
About Single Cell Network Profiling
Single Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signaling networks in immunology and cancer. SCNP, by measuring functional signaling network behavior at the level of the single cell, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of functional cellular heterogeneity in otherwise molecularly and phenotypically homogeneous tissues, including the identification of rare cell subsets such as drug-resistant and stem cells. As such, the technology has widespread application in preclinical drug development, clinical drug development and diagnostic development.
Nodality is a next-generation life sciences company that is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to reveal biology, define disease, and improve health. Nodality's unique, innovative, and proprietary platform, Single Cell Network Profiling or SCNP, enables the promise of precision medicine by unlocking the potential of therapeutics and by matching therapies with the right patients. SCNP enables functional characterization of disease-associated signaling at the individual patient level, enabling optimization of treatment tailored to target the biology driving the disease. Nodality is applying SCNP to develop molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the lead products targeting treatment management in hematological malignancies. Nodality is also collaborating with Pharma partners on patient stratification & companion diagnostics development, drug & disease profiling, determination of mechanism of action, mechanism-based competitive differentiation, whole blood PD assays, and biomarker discovery & development. These applications can result in increased probability of success, reduced timeline for clinical development, and differentiation from competitors in the marketplace. Nodality established multi-year pharma strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB) and Pfizer (NYSE: PFE) in 2012 utilizing its SCNP technology to assist the development of several compounds focusing initially on immunology disorders. For more information on Nodality, please visit www.nodalityinc.com.